Premium
Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit
Author(s) -
Cowan A.,
Raffa R.B.,
Tallarida C.S.,
Tallarida R.J.,
Christoph T.,
Schröder W.,
Tzschentke T.M.
Publication year - 2014
Publication title -
european journal of pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.305
H-Index - 109
eISSN - 1532-2149
pISSN - 1090-3801
DOI - 10.1002/j.1532-2149.2014.00461.x
Subject(s) - tapentadol , pharmacology , analgesic , opioid , chemistry , antagonist , medicine , receptor , biochemistry
Background A multi‐mechanistic approach offers potential enhancement of analgesic efficacy, but therapeutic gain could be offset by an increase in adverse events. The centrally acting analgesic tapentadol [( – )‐(1 R ,2 R )‐3‐(3‐dimethylamino‐1‐ethyl‐2‐methyl‐propyl)‐phenol hydrochloride] combines μ‐opioid receptor ( MOR ) agonism and neuronal noradrenaline reuptake inhibition ( NRI ), both of which contribute to its analgesic effects. Previously, isobolographic analysis of occupation‐effect data and a theoretically equivalent methodology determining interactions from the effect scale demonstrated pronounced synergistic interaction between the two mechanisms of action of tapentadol in two models of antinociception (low‐intensity tail‐flick and spinal nerve ligation). The present study investigated the nature of interaction of the two mechanisms on a surrogate measure for gastrointestinal adverse effect (inhibition of gastrointestinal transit). Methods Dose–response curves were generated in rats for tapentadol alone or in combination with the opioid receptor antagonist, naloxone, or the α 2 ‐adrenoceptor antagonist, yohimbine, to reveal the effect of tapentadol based upon MOR agonism, NRI , and combined mechanisms. Results The dose–effect curve of tapentadol was shifted to the right by both antagonists, thereby providing data to distinguish between MOR agonism and NRI . Analysis revealed a simple additive interaction between the two mechanisms on this endpoint, in contrast to the synergistic interaction previously demonstrated for antinociception. Conclusions We believe this is the first published evaluation of mechanistic interaction for a surrogate measure of adverse effect of a single compound with two mechanisms of action, and the results suggest that there is a greater separation between the analgesic and gastrointestinal effects of tapentadol than expected based upon its analgesic efficacy.